Bipolar disorder is a highly heritable psychiatric disorder. We performed a genome-wide association study (GWAS) including 20,352 cases and 31,358 controls of European descent, with follow-up analysis of 822 variants with P < 1 × 10 −4 in an additional 9,412 cases and 137,760 controls. Eight of the 19 variants that were genome-wide significant (P < 5 × 10 −8 ) in the discovery GWAS were not genome-wide significant in the combined analysis, consistent with small effect sizes and limited power but also with genetic heterogeneity. In the combined analysis, 30 loci were genome-wide significant, including 20 newly identified loci. The significant loci contain genes encoding ion channels, neurotransmitter transporters and synaptic components. Pathway analysis revealed nine significantly enriched gene sets, including regulation of insulin secretion and endocannabinoid signaling. Bipolar I disorder is strongly genetically correlated with schizophrenia, driven by psychosis, whereas bipolar II disorder is more strongly correlated with major depressive disorder. These findings address key clinical questions and provide potential biological mechanisms for bipolar disorder.
B
ipolar disorder (BD) is a severe neuropsychiatric disorder characterized by recurrent episodes of mania and depression that affect thought, perception, emotion and social behavior. A lifetime prevalence of 1−2%, elevated morbidity and mortality, onset in young adulthood and a frequently chronic course make BD a major public health problem and a leading cause of the global burden of disease 1 . Clinical, twin and molecular genetic data all strongly suggest that BD is a multifactorial disorder 2 . On the basis of twin studies, the overall heritability of BD has been estimated to be more than 70% (refs. 3, 4 ), suggesting a substantial involvement of genetic factors in the development of the disorder, although non-genetic factors also influence risk.
BD can be divided into two main clinical subtypes 5, 6 : bipolar I disorder (BD1) and bipolar II disorder (BD2). In BD1, manic episodes typically alternate with depressive episodes during the course of illness. BD2 diagnosis is based on the lifetime occurrence of at least one depressive and one hypomanic (but not manic) episode. Although modern diagnostic systems retain the Kraepelinian dichotomy 7 between BD and schizophrenia (SCZ), the distinction between the two disorders is not always clear-cut and patients who display clinical features of both disorders may receive a diagnosis of schizoaffective disorder-bipolar type (SAB). Likewise, in genetic studies, BD and SCZ are usually treated separately, although recent epidemiological and molecular genetic studies provide strong evidence for some overlap between the genetic contributions to their etiology 2, 8 . Recent genome-wide association studies in BD have identified a number of significant associations between disease status and common genetic variants [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The first large collaborative BD GWAS by the multinational Psychiatric Genomics Consortium (PGC) Bipolar Disorder Working Group comprised 7,481 patients with BD and 9,250 controls and identified four genome-wide-significant loci 9 . Three subsequent meta-analyses that included the PGC BD data 10, 12, 18 identified an additional four loci. Estimates of the proportion of variance in liability attributable to common variants genome wide (SNP heritability) indicate that ~30% of the heritability for BD is due to common genetic variants 8 . So far, only a small fraction of this heritability is explained by associated loci, but results from other human complex traits suggest that many more will be identified by increasing the sample size of GWAS 24 . Here, we report the second GWAS of the PGC Bipolar Disorder Working Group, comprising 20,352 cases and 31,358 controls of European descent in a single, systematic analysis, with follow-up of top findings in an independent sample of 9,412 cases and 137,760 controls. Some of our findings reinforce specific hypotheses regarding BD neurobiology; however, the majority of the findings suggest new biological insights.
Results

GWAS of BD.
We performed a GWAS meta-analysis of 32 cohorts from 14 countries in Europe, North America and Australia (Supplementary Table 1a ), totaling 20,352 cases and 31,358 controls of European descent (effective sample size 46,582). This is a large GWAS of BD, a 2.7-fold increase in the number of cases compared with our previous GWAS 9 and includes 6,328 case and 7,963 control samples not previously reported. We imputed variant dosages using the 1000 Genomes reference panel, retaining association results for 9,372,253 autosomal variants with imputation quality score INFO > 0.3 and minor allele frequency (MAF) ≥1% in both cases and controls. We performed logistic regression of case status on imputed variant dosage using genetic ancestry covariates. The resulting genomic inflation factor (λ GC ) was 1.23, 1.01 when scaled to 1,000 cases and 1,000 controls (λ 1,000 ) ( Supplementary Fig. 1 ). The linkage disequilibrium (LD) score regression intercept was 1.021 (s.e.m. = 0.010), and the attenuation ratio of 0.053 (s.e.m. = 0.027) was non-significant, indicating that the observed genomic inflation is indicative of polygenicity rather than stratification or cryptic population structure 25 . The LD score regression SNP heritability estimates for BD were 0.17-0.23 on the liability scale assuming population prevalence of 0.5-2% (see Supplementary  Table 1a , Methods and Supplementary Note for sample and method details).
We found a marked increase in phenotypic variance explained by genome-wide polygenic risk scores (PRS) compared with previous publications (sample size weighted-mean-observed Nagelkerke's R 2 = 0.08 across datasets, liability scale R 2 = 0.04, for P threshold of 0.01; Supplementary Fig. 2 and Supplementary Table 2 ). Among the different datasets, we observed no association between the PRS R 2 A full list of authors and affiliations appears at the end of the paper.
and: (1) the sex distribution of the BD cases (P = 0.51); (2) the proportion of cases with psychosis (P = 0.61); (3) the proportion with a family history of BD (P = 0.82); or (4) the median age of onset for BD (P = 0.64). In our primary genome-wide analysis, we identified 19 loci exceeding genome-wide significance (P < 5 × 10 −8
; Table 1 ).
Follow-up of suggestive loci in additional samples. We tested lead variants that were significant at P < 1 × 10 −4 in our discovery GWAS meta-analysis, comprising a total of 794 autosomal and 28 X-chromosome variants, for association in follow-up samples totaling 9,412 cases and 137,760 controls of European ancestry (effective sample size 23,005; Supplementary Note and Supplementary Table 1b ). We first compared discovery and follow-up sample summary statistics using LD score regression, and estimated their genetic correlation to be 0.98 (s.e.m. = 0.07), consistent with homogeneous genetic effects between the two samples. Discovery and follow-up samples also show similar patterns of significant genetic correlations with a range of other human diseases and traits in the LD Hub database 26 (Supplementary Table 3 ; correlation of 0.93, P = 8.3 × 10
, Supplementary Fig. 3 ). Thirty autosomal loci achieved genome-wide significance (P < 5 × 10
) in fixed-effect meta-analysis of our GWAS and follow-up samples (Fig. 1, Table 1a , Supplementary Data 1-3 and Supplementary Table 4 ). In Supplementary Table 5 , we present detailed descriptions of the associated loci and genes, with bioinformatic and literature evidence for their potential roles in BD. Of the 30 genome-wide-significant loci from our combined analysis, 20 are novel BD risk loci. These include 19 loci that were significant only in the combined analysis, of which 3 were reported to have genome-wide-significant SNPs in previous studies (ADCY2 (ref. 18 ), POU3F2 (ref. 18 ), ANK3 (refs. 12, 18 )), and 11 that were significant in our primary GWAS. We refer to loci by the gene name attributed in previous BD GWAS publications, or by the name of the closest gene for newly identified loci, without implication that the named gene is causal. Results for all variants tested in the follow-up study are presented in Supplementary Table 4 .
Of the 19 variants that were genome-wide significant in the discovery GWAS, 8 were not genome-wide significant in the combined analysis (Table 1b) , and 11 were non-significant in one-tailed association tests in the follow-up samples (P > 0.05 in Table 1 ). Still, the follow-up results for these 19 variants are clearly non-null in aggregate: all 19 had consistent directions of effect between discovery GWAS and follow-up (9.5 expected by chance, binomial test P = 4 × 10 −6 ), and 8 of the 19 had follow-up one-tailed P < 0.05 (1 expected by chance, sign test P = 2 × 10 −6 ). Using effect sizes corrected for winner's curse 27, 28 for each of the 19 variants that were genome-wide significant in the GWAS, we calculated power to achieve significant results (one-tailed P < 0.05) in the followup samples or genome-wide significance in combined analysis (Supplementary Note, Supplementary Table 6 and Supplementary  Fig. 4 ). We found that the number of variants significant in followup was close to expectation (8 observed with follow-up P < 0.05, 8.26 expected, Poisson binomial P = 0.57), and that 11 variants achieving genome-wide significance in the combined analysis were also within the expected range (P = 0.29). As an alternative to winner's curse correction, we conducted a polygenic inference analysis using a mixture of Gaussian effect size distributions to model BD genetic architecture and estimate the variants' true effect sizes 29 (Supplementary Note and Supplementary Fig. 5 ). Under this model, we found that only two variants were nominally significantly weaker in follow-up than expected by chance (TRANK1, rs9834970 P = 0.012, and rs13821 P = 0.026; Supplementary Table 7) , and none were Bonferroni significant (P > 0.05/19 = 0.0026). Thus, the overall replication rate is within the expected range given the polygenic architecture of BD.
We next asked if the variants tested in the follow-up samples were, in aggregate, consistent with the presence of additional sub genome-wide-significant BD association signals. After excluding 47 variants that were genome-wide significant in our GWAS, our combined analysis or previous BD GWAS, 775 variants remained in our follow-up experiment. Of these, 551 variants had the same direction of effect in the discovery GWAS and follow-up (71%, compared to a null expectation of 50%, sign test P = 1.3 × 10 −32 ), and 110 variants had the same direction of effect and were nominally significant (P < 0.05) in the follow-up (14%, compared to an expected value of 5%, binomial test P = 2.1 × 10
−22
). This consistency between our GWAS and follow-up results suggests that many more true BD associations exist among these variants.
To identify additional independent signals, we conducted conditional analyses across each of the 30 significant BD loci (Supplementary Table 8 ). We used the effective number of independent variants on the basis of LD structure within loci 30 to calculate a multiple test-corrected significance threshold (P = 1.01 × 10 −5 , see Supplementary Note). Only one locus showed evidence for an independent association signal (rs114534140 in locus no. 8, FSTL5; P conditional = 2 × 10 −6 ). At another locus (no. 30, STK4 on chromosome 20), we found two SNPs with genome-wide significance in low LD (r 2 < 0.1); however, conditional analysis showed that their associations were not independent.
Shared loci and genetic correlations with other traits. We next examined the genetic relationships of BD to other psychiatric disorders and traits. Of the 30 genome-wide-significant BD loci, 8 also harbor schizophrenia (SCZ) associations 31, 32 . On the basis of conditional analyses, the BD and SCZ associations appear to be independent at three of the eight shared loci (NCAN, TRANK1 and chr7q22.3:105 megabases (Mb)) (Supplementary Table 9 ). No genome-wide-significant BD locus overlapped with those identified for depression (DEPR), including 44 risk loci identified in the most recent PGC GWAS of major depression 33 and those reported in a large study of depressive symptoms or subjective well-being 34 . As previously reported 35 , we found substantial and highly significant genetic correlations between BD and SCZ 31 (LD score regression estimated genetic correlation r g = 0.70, s.e.m. = 0.020) and between BD and DEPR 33 (r g = 0.35, s.e.m. = 0.026). The BD and DEPR genetic correlation was similar to that observed for SCZ and DEPR (r g = 0.34, s.e.m. = 0.025) (Supplementary Table 10a ).
We found significant genetic correlations between BD and other psychiatric-relevant traits (Supplementary Table 10b ), including autism spectrum disorder 8 (r g = 0.18, P = 2 × 10
), anorexia nervosa 36 (r g = 0.23, P = 9 × 10
) and subjective well-being 34 (r g = −0.22,
). There was suggestive positive overlap with anxiety disorders (r g = 0.21, P = 0.04) 37 and neuroticism (r g = 0.12, P = 0.002) 38 . Significant r g values were seen with measures of education: college attendance 39 (r g = 0.21, P = 1 = x10
) and education years 40 (r g = 0.20,
), but not with childhood IQ 41 (r g = 0.05, P = 0.5) or intelligence 42 (r g = −0.05, P = 0.08). Among a large number of variants in BD risk loci that were associated with additional traits in the GWAS catalog 43 , we found a handful of loci with non-independent associations (in one overlapping locus with each of educational attainment, biliary atresia, bone mineral density and lipid-related biomarkers) (Supplementary Table 9 ). Biliary atresia and lipid-related biomarkers, however, did not show significant genetic correlation with BD (Supplementary Table 10b ).
BD subtypes.
We performed a secondary GWAS focusing on three clinically recognized subtypes of bipolar disorder: BD1 (n = 14,879 cases), BD2 (n = 3,421 cases) and SAB (n = 977 cases) (Supplementary Note, Supplementary Tables 1a and 11 and Supplementary Fig. 6 ). We observed variants in 14 loci with genome-wide significance for BD1, 10 of which were in genome-wide-significant loci in the combined BD GWAS analysis. Not surprisingly, given the sample overlap, three of the four remaining loci genome-wide significant for BD1 have P < 10 −6 in either our discovery GWAS or combined analysis. The remaining locus (MAD1L1, chr7:1.9 Mb, discovery GWAS P = 2.4 × 10
) was recently published in two BD GWAS that included Asian-ancestry samples 17, 44 . We did not observe genome-wide-significant results for the smaller BD2 and SAB analyses. BD1, BD2 and SAB all have significant common variant heritabilities (BD1 h Table 12 ). We conducted PRS analyses to explore the relationship between genetic risk of SCZ and DEPR, and BD subtypes and psychosis ( Fig. 2 and Supplementary Table 13 ). PRS calculated from SCZ 31 were significantly higher in BD1 cases than in BD2 cases (P = 5.6 × 10 −17
, P threshold = 0.1) and in cases with psychosis compared to those without psychosis (P = 2.12 × 10 −6
, P threshold = 0.1). Conversely, PRS calculated from DEPR 33 were significantly higher in BD2 cases than in BD1 cases (P = 8.5 × 10 Table 12 ).
Systems biology and in silico functional analyses. We tested for functional genomic enrichment in our BD GWAS using partitioned LD score regression and a range of functional annotations across tissues 45 (Supplementary Note and Supplementary Table 14) . SNP-based BD heritability was most enriched in open chromatin annotations in the central nervous system (proportion SNPs = 0.14, proportion h 2 snp = 0.60, enrichment = 3.8, P = 3 × 10
−14
). We also used DEPICT 46 to test for expression of BD-associated genes across tissues, and found significant enrichment of central nervous system (P < 1.4 × 10
, false discovery rate (FDR) < 0.01) and neurosecretory system (P = 2.0 × 10
, FDR < 0.01) genes (Supplementary Table 15 ). To prioritize genes that may play a functional role in BD, we integrated BD GWAS association statistics with eQTL (SNP-gene expression association) and mQTL (SNP-DNA methylation association) data using summary Mendelian randomization (SMR) [47] [48] [49] (Supplementary Table 16 and Supplementary Note). SMR identified 21 genes using eQTL data that were significant after multiple testing correction, without evidence of heterogeneity between GWAS and eQTL association signals. Association with GNL3 was observed in both brain and blood, highlighting the utility of using blood eQTL data as proxy for brain eQTLs 49 . Methylation profiles at six CpGs in the brain and ten CpGs in the blood were associated with BD, four of which overlapped between brain and blood mQTL: MUSTN1, GLT8D1, HAPLN4 and FADS2.
Finally, we used MAGMA 50 to conduct a gene-wise BD GWAS and to test for enrichment of pathways curated from multiple sources (see Supplementary Note). We note that significance levels were assigned to genes by physical proximity of SNPs, and do not imply that significant genes are causal for BD. Genic association results included 154 Bonferroni significant genes (MAGMA P JOINT < 2.8 × 10 −6 ), including 82 genes in 20 genome-wide-significant loci, and 73 genes in 27 additional loci that did not reach genome-wide significance (Supplementary Table 17 ). Nine related pathways were significantly enriched for genes with BD associations (P < 7.0 × 10
, FDR < 0.05), including abnormal motor coordination/balance pathways (from mice), regulation of insulin secretion and endocannabinoid signaling (Supplementary Table 18 and Supplementary Fig. 7 ).
Discussion
We carried out a large bipolar disorder GWAS and identified 30 genome-wide-significant loci, including 20 that were newly identified. Previous BD GWAS have reported a total of 20 loci significantly associated with BD [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ; 12 of these previously reported loci were not genome-wide significant in our GWAS meta-analysis, but all had P GWAS ≤ 1.3 × 10 −5 (Supplementary Table 4c ). Our recent GWAS of BD and SCZ 51 , which included our discovery GWAS data jointly analyzed with published SCZ data 31 (without overlapping control subjects), highlighted similarities and differences in BD ). Combined GWAS + follow-up −log 10 P for lead SNPs reaching genome-wide significance in either GWAS or combined analysis (triangles, inverted if GWAS + follow-up −log 10 P > GWAS −log 10 P). Labels correspond to gene symbols previously reported for published loci (black) and the nearest genes for newly identified loci (blue), at top if GWAS + follow-up P < 5 × 10
. Loci with one-tailed follow-up P > 0.05 (Table 1) have dotted underlined locus names.
and SCZ in terms of known associated SNPs and PRS-subphenotype associations; here, we maximized power to identify BD associations. The phenotypic variance explained by PRS on the basis of our BD GWAS data is ~8% (observed scale; 4% on the liability scale 52 ), an increase from 2.8% (1.2% on the liability scale) in our previous study 9 . The results of our BD subtype PRS analyses support the nosological distinction between BD1 and BD2, but also highlight the importance of psychosis beyond DSM subtypes, corroborating and expanding evidence from previous clinical 53 and genetic studies 51, 54, 55 . The DEPR versus BD PRS analyses provide further support for the distinction between BD1 and BD2, independent of the presence of psychosis.
Of the 19 loci identified in our discovery GWAS, only 11 were genome-wide significant in meta-analysis of our GWAS and follow-up samples. These results are not unexpected given the small effect sizes and the winner's curse 28, 56 (Supplementary Note and Supplementary Fig. 4) ; SNPs can teeter-totter around the genomewide-significance threshold even as sample sizes increase. Genetic heterogeneity observed among BD GWAS cohorts 8 could also contribute to inconsistent replication results; we observed variable polygenic effects between BD subtypes ( Fig. 2 and Supplementary  Table 13 ) as well as between cohorts in our study ( Supplementary  Fig. 2 and Supplementary Table 4) which used a diversity of criteria to define cases (Supplementary Note). Remarkably, the strongest association signal from the discovery GWAS, at the TRANK1 locus (rs9834970; P combined = 5.7 × 10 −12
, odds ratio, OR = 0.93), exhibited significant heterogeneity among discovery GWAS cohorts (Cochran's Q P = 1.9 × 10 −4 ), and did not replicate in the follow-up sample (one-tailed P follow-up = 0.15) (Supplementary Data 2 and 3) . This locus has been significant in recent 11, 12, 17, 18 but not earlier BD GWAS 9, 13, 20 . Thus, complex genetic architecture as well as phenotypic heterogeneity may contribute to the inconsistency of genomewide-significant findings within and across BD GWAS studies. The observed heterogeneity is a major challenge for GWAS of psychiatric disorders and calls for careful and systematic clinical assessment of cases and controls in parallel with continued efforts to collect larger sample sizes.
Of the 30 BD-associated loci, 8 also harbor associations 31,32,57 with schizophrenia (SCZ); however, conditional analyses suggest that the BD and SCZ associations at three of the eight shared loci (in the NCAN, TRANK1 and chr7q22.3:105 Mb loci) may be independent (Supplementary Table 9 ). Differential BD and SCZ associations may represent opportunities to understand the genetic distinctions between these closely related and sometimes clinically difficult to distinguish disorders. We did not find BD loci that overlap with those associated with major depression 33 . The confirmed association within loci containing CACNA1C and other voltage-gated calcium channel genes supports the rekindled interest in calcium channel antagonists as potential treatments for BD, with similar examination ongoing for other genes implicated in SCZ GWAS 58 . Other genes within novel BD-associated loci include those coding for other ion channels and transporters (SCN2A, SLC4A1), neurotransmitter receptors (GRIN2A) and synaptic components (RIMS1, ANK3). Further study will confirm whether or not these are the causal genes in the loci. These processes are important in neuronal hyperexcitability 59 , an excess of which has been reported in induced pluripotent-stemcell-derived neurons from patients with BD, and which has been shown to be affected by the classic mood-stabilizing drug lithium . Top genes appearing in these pathways include calcium and potassium channel subunits, MAP kinase and GABA-A receptor subunit genes (Supplementary Table 18 ).
We observe significant positive genetic correlations with educational attainment, but not with either adult or childhood IQ, suggesting that the role of BD genetics in educational attainment may be independent of general intelligence. This result is inconsistent with suggestions from epidemiological studies 67 , but in agreement with results from a recent clinical study 68 . In summary, findings from the genome-wide analysis of BD reveal an extensive polygenic genetic architecture of the disease, implicate brain calcium channels and neurotransmitter function in BD etiology, and confirm that BD is part of a spectrum of highly correlated psychiatric and mood disorders.
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Replication
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